Robert (Bob) Anderson

Chief Scientific Officer

Dr Anderson PhD, FRACP, is the co-founder, CEO, CSO, CMO and Director of Nexpep.

Dr Anderson holds a doctorate and specialist qualifications in internal medicine and gastroenterology and is a recognised international leader in the immunology and clinical management of coeliac disease.

Dr Anderson’s research has lead to the four patents that protect Nexpep’s core technology and lead compound, Nexvax2. Published in 2000 (Nature Medicine 6, 337-342), his work at Oxford University revealed that the toxic components of gluten could be simply studied in patients with coeliac disease using their blood shortly after they consumed gluten.

After returning to the prestigious Walter and Eliza Hall Institute in Melbourne, Australia, where he is now a Laboratory Head in the Autoimmunity and Transplantation Division, Dr Anderson established high throughput screening to map out the entire T-cell response to gluten in patients with coeliac disease.

After the founding of Nexpep in 2005, Dr Anderson has overseen the preclinical and early clinical development of Nexvax2.

Dr Anderson is a frequent invited speaker at local, national, and international clinical and scientific meetings.